How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

Published:2015-10-08 Issue:15 Volume:126 Page:1860-1861
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Prasad Vinay¹²^ORCID,Mailankody Sham¹³

Affiliation:

1. Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD

2. Hematology-Oncology Service, Knight Cancer Center, Oregon Health & Sciences University, Portland, OR

3. Myeloma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/15/1860/1390106/1860.pdf

Reference8 articles.

1. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.;Saret;Blood,2015

2. Bias in published cost effectiveness studies: systematic review.;Bell;BMJ,2006

3. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.;Hayslip;Clin Lymphoma Myeloma,2008

4. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.;van Oers;Blood,2006

5. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.;van Oers;J Clin Oncol,2010

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars in the practice of modern oncologist;Cancer Urology;2024-02-29

2. Malignant: How Bad Policy and Bad Evidence Harm People with Cancer, by Vinay Prasad, Baltimore, Maryland, Johns Hopkins University Press, 2020.;Cambridge Quarterly of Healthcare Ethics;2022-03-04

3. Valuing treatment in oncology: embracing a broader notion of value;Journal of Managed Care & Specialty Pharmacy;2022-03

4. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-05-02

5. Approval and Coverage of Cancer Drugs in England, Canada, and the US;JAMA Internal Medicine;2021-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3